Every earnings call for GLAXO — management tone, guidance, KPIs and promise tracking, quarter by quarter.
GLAXO · 4 transcripts · Healthcare · latest Q4 FY26GlaxoSmithKline Pharmaceuticals Limited has 4 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Full Year EBITDA grew double digit at 11%.
Read full transcript & analysisRevenue (Standalone) ₹1,000 cr (+8% YoY); EBITDA Margin 35.9%; PAT Margin 27.3%. Consolidated revenue grew ~10% to cross INR 1,000 crores for the first time in a quarter.
Read full transcript & analysisRevenue (Full Year) ₹3,723 cr (+9% YoY); EBITDA (Full Year) ₹1,169 cr (+30% YoY); EBITDA Margin (Full Year) 31%. Full year revenue of INR 3723 crores, up 9% YoY.
Read full transcript & analysisEBITDA ₹290 cr (+33% YoY); EBITDA Margin 30.7%. Revenue grew 18% YoY, driven by double-digit growth across all business segments.
Read full transcript & analysis